Xenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022. In the quarter to June 2026, revenue grew 100.7%, EPS fell 3.74% and free cash flow fell 48.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow XENE
Xenon Pharmaceuticals Inc. (XENE) EV/Sales
As of 16 October 2026, Xenon Pharmaceuticals Inc. (XENE) trades at a EV/Sales of 144×. Over the past ten years it has ranged from −9.3× (August 2017) to 593× (July 2019); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 179× | 39.42% |
| FY2022 | 128× | 182.45% |
| FY2021 | 45.4× | 283.77% |
| FY2020 | 11.8× | (60.72%) |
| FY2019 | 30.1× | (37.24%) |
| FY2017 | 48.0× | 50.64% |
| FY2016 | 31.9× | 783.90% |
| FY2015 | 3.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 125× | (6.00%) |
| Sep 2022 | 133× | 196.98% |
| Jun 2022 | 44.8× | (12.22%) |
| Mar 2022 | 51.0× | 12.28% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| VKTX Viking Therapeutics, Inc. compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.3× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 7.8× |
| DNLI Denali Therapeutics Inc. compare | 8.6× |
| IDYA IDEAYA Biosciences, Inc. compare | 9.4× |
| XENE Xenon Pharmaceuticals Inc. | 144× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)